Naklofen (Diclofenac Sodium)

Diclofenac sodium works by reversibly inhibiting cyclooxygenase enzymes COX‑1 and COX‑2, which lowers the production of prostaglandins—key mediators of inflammation, pain, and fever. By reducing prostaglandin synthesis, the drug diminishes inflammatory responses and alleviates pain at the affected site.

The specific dose and frequency of Naklofen are determined by the prescribing clinician based on the patient’s condition, weight, and clinical response. Healthcare providers tailor the regimen to achieve optimal pain control while minimizing potential risks.

The safety of diclofenac sodium in pregnancy and lactation has not been definitively established. It is generally avoided unless clearly needed, and the benefits must outweigh potential risks. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Naklofen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any cold‑chain requirements—and necessary import documentation.

Naklofen (diclofenac sodium) offers potent anti‑inflammatory and analgesic effects similar to other NSAIDs such as ibuprofen or naproxen, but it is delivered as an intramuscular injection, providing rapid systemic exposure. Compared with oral NSAIDs, the injectable form may be preferred when oral administration is not feasible or when a quicker onset is required.

Naklofen should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Do not freeze the product. Before administration, inspect the solution for particulate matter or discoloration and use aseptic technique.

Naklofen is given by intramuscular injection into a suitable muscle, typically the deltoid or gluteal region, by a qualified healthcare professional. The injection should be performed using aseptic technique, and the dose is administered as prescribed.

Serious risks include gastrointestinal bleeding or ulceration, severe liver injury, acute kidney damage, cardiovascular events such as heart attack or stroke, and life‑threatening allergic reactions like anaphylaxis. Patients should be monitored for signs of these conditions, and therapy should be discontinued if they occur.

Naklofen is contraindicated in patients with known hypersensitivity to diclofenac or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe heart failure, and individuals who have experienced a previous severe allergic reaction to injectable NSAIDs. Caution is also advised for patients with impaired renal or hepatic function.